Clinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen
The Oncologist · 01.09.2025 · 30 (9)
DOI: 10.1093/oncolo/oyaf231 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 24.07.2025. Verfasst von Thaer Khoury und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Our objective is to compare the response rate between two matched cohorts of early-stage TNBC (chemotherapy: CT + immune checkpoint inhibitor: ICI vs CT alone) and to define clinicopathological variables to identify a subgroup of patients who could be spared or benefit from ICI.
Methods
Patients treated with CT + ICI according to KEYNOTE-522 (KN-522) (n = 128) were included in the study and matched 1:1 with patients treated with CT alone. Matching criteria included age range (10 years), race, clinical stage (c)-AJCC, and histological type (metaplastic [MpBC] vs no special type [IC-NST]). The following histological characteristics in the core needle biopsy (CNB) were included: histological type, Nottingham grade, degree of necrosis, and percentage of tumor-infiltrating lymphocytes (TILs). The residual cancer burden (RCB) was categorized into 0 (pCR), I, II, or III. To identify a subgroup of patients who could be spared or benefit from adding ICI, an analysis of the penalized maximum likelihood estimate was performed. Results pCR was achieved in 50% of patients treated with CT + ICI vs 35.9% treated with CT alone (P = .02). In the CT group, lower TILs in CNB, non-Black race, MpBC histology, and a higher degree of necrosis were associated with non-pCR. Patients were categorized into quartiles (Q) based on the predicted risk of non-pCR to CT (Q1 represents the lowest risk and Q4 represents the highest risk of non-pCR). In Q4, the pCR rate with CT alone was only 2.9% (1/46) vs 20% (6/64) in the CT + IT cohort (P = .044). The following variables were associated with Q4 vs Q1-3: non-Black race (96.9% vs 88%, P = .04), MpBC histology (29.7% vs 1.6%, P < .01), lymph node positive disease (54.6% vs 50%, P < .01), Nottingham grade 2 (32.8% vs 6.3%, P < .01), and lower mean TILs (12.8 ± 15 vs 36.7 ± 26.5, P < .01).
Conclusions
The efficacy of CT + ICI regimen in the real world, although higher than CT, is lower than that observed on the KN 522 clinical trial. Our results need validation in a larger cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
- Department of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
- Department of Pathology, Wexner Medical Center at The Ohio State University, Columbus, OH, United States.
- Department of Pathology, Division of Anatomic Pathology, University of California San Diego Health, San Diego, CA, United States.
- Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
- Pelotonia Institute for Immuno-Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
ORCID-Profile: Thaer Khoury, Song Yao
Förderung
- NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Khoury, T., Gandhi, S., Tozbikian, G., Fadare, O., Syed, S., To, B., Quiroga, D., Yao, S., Attwood, K., Yu, H., & Fang, Y. (2025). Clinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen. The Oncologist, 30(9). https://doi.org/10.1093/oncolo/oyaf231
Vancouver
Khoury T, Gandhi S, Tozbikian G, Fadare O, Syed S, To B, et al. Clinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen. The Oncologist. 2025;30(9). doi:10.1093/oncolo/oyaf231
BibTeX
@article{Khoury2025,
author = {Khoury, Thaer and Gandhi, Shipra and Tozbikian, Gary and Fadare, Oluwole and Syed, Samira and To, Briana and Quiroga, Dionisia and Yao, Song and Attwood, Kristopher and Yu, Han and Fang, Yisheng},
title = {Clinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {9},
doi = {10.1093/oncolo/oyaf231}
}
EUVIMED